| Z-Ile-Leu-aldehydepotent gamma-Secretase inhibitor |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
Chemical structure
Z-Ile-Leu-aldehyde Dilution Calculator
calculate
Z-Ile-Leu-aldehyde Molarity Calculator
calculate
| Cas No. | 161710-10-7 | SDF | Download SDF |
| Chemical Name | benzyl ((2R,3R)-3-methyl-1-(((R)-4-methyl-1-oxopentan-2-yl)amino)-1-oxopentan-2-yl)carbamate | ||
| Canonical SMILES | O=C(N[C@@H](C(N[C@@H](C=O)CC(C)C)=O)[C@@H](CC)C)OCC1=CC=CC=C1 | ||
| Formula | C20H30N2O4 | M.Wt | 362.46 |
| Solubility | ≥10.8mg/mL in DMSO | Storage | Store at -20°C |
| Physical Appearance | A solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
Z-Ile-Leu-aldehyde (gamma-Secretase inhibitor XII /GSI XII, Z-IL-CHO) is a potent gamma-Secretase inhibitor and Notch signaling inhibitor.
Notch signaling impinges on many cellular processes, including cell proliferation, differentiation, apoptosis, and maintenance of stem cells. It is also involved in many developmental systems, including neurogenesis, angiogenesis, hematopoiesis, and myogenesis. Deregulation of Notch signaling leads to developmental syndromes and cancer [3]. In order to transmit a signal, Notch receptors undergo a series of proteolytic cleavages after binding their cognate ligands of the Delta-like and Jagged family. γ-Secretase is a large protease complex that cleaves the membrane-bound form of Notch and releases the intracellular domain of the Notch receptor. This step in Notch signaling is pivotal in the activation of this signaling cascade [1] [2].
In vitro: GSI XII (10~15 µM) blocked the Notch signaling, reduced cell viability and induced apoptosis in MOPC315.BM murine multiple myeloma cells in vitro. GSI XII (10 µM) impaired murine osteoclast differentiation of receptor activator of NF-κB ligand (RANKL)-stimulated RAW264.7 murine monocyte/macrophage cell line [1]. GSI XII (8 μM ~ 15 μM) potently triggered an apoptotic response through inhibition of Notch activity in the breast cancer cells. GSI XII also targets mammary cancer stem-like cells because it dramatically prevented in vitro mammosphere formation [3].
In vivo: Notch inhibition through GSI XII (intraperitoneal injection, 10 mg/kg) reduced myeloma-specific paraprotein levels, bone loss and diminished osteolytic lesions in the MOPC315.BM mice model[1]. Notch inhibition using GSI XII (intraperitoneal injection, 5 mg/kg) blocked embryonal rhabdomyosarcoma tumorigenesis in mice[2].
ex vivo: A model of 3D culture of human breast cancer tissues was developed to study a series of 30 consecutive primary tumors from patients with untreated breast cancer for their sensitivity to the Notch inhibitor GSI XII (15 μM). The results indicated that 24 tumors are sensitive to apoptosis induction by GSIXII.
References:[1]. Schwarzer R, Nickel N, Godau J, et al. Notch pathway inhibition controls myeloma bone disease in the murine MOPC315. BM model[J]. Blood cancer journal, 2014, 4(6): e217.[2]. Belyea B C, Naini S, Bentley R C, et al. Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis[J]. Clinical Cancer Research, 2011, 17(23): 7324-7336.[3]. Séveno C, Loussouarn D, Bréchet S, et al. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells[J]. Breast Cancer Research, 2012, 14(3): R96.
